GILD stock surged higher on January 19, 2021, after Morgan Stanley upgraded the stock.
Bullish option flow was detected in GILD stock.
Make sure to review this lesson on options trading so that you understand the chart above.
Morgan Stanley analyst Matthew Harrison upgraded Gilead to Overweight from Equal Weight with a price target of $83, up from $67. He believes success is likely in the ongoing Trodelvy Phase 3 study in third-line plus patients and thinks hormone receptor-positive metastatic breast cancer could represent “billions in additional peak sales,” Harrison tells investors. He also believes the combination of Gilead’s long-acting HIV capsid inhibitor, lenacapavir, with another long-acting HIV drug presents an opportunity to extend HIV cash flows “into the 2040s,” or potentially another 10 years, said the analyst, who calls 2021 a “pivotal pipeline year” for Gilead.